A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months

Completed

Conditions studied: Multiple Sclerosis

In brief

To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population of healthy controls.

Key facts

Study ID: NCT01695434
Run by: University at Buffalo
People needed: 60
Starts: 2012-06-01
Expected to finish: 2013-02-01
Last updated by the study team: 2013-03-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

MS patients diagnosed with clinically definite MS according to the McDonald criteria (Polman et al., 2005)
Being on GA monotherapy (20mg/day sc) for at least 24 months prior to the 24-month MRI scan
Having baseline clinical MRI scan that included SWI-filtered phase imaging in a 12-month window from the start day of the of the GA (MS patients)
Having baseline clinical MRI scan that included SWI-filtered phase imaging (healthy controls)
MS patients having a RR disease course (Lublin and Reingold, 1996)
Age 18-65 (healthy controls will be matched to MS patients for age and sex)
Signed informed consent at the 24-month follow-up
Pass MRI health screening
MS patients passing contrast screening
MS patients having normal kidney function (creatinine clearance >59)
None of the exclusion criteria

You may not qualify if…

Patients who had a relapse within 30 days prior to MRI baseline scan date
Patients who received steroid treatment within 30 days prior to the MRI baseline scan date
Women who are pregnant, lactating or of childbearing age who do not consent to approved contraceptive use during the study
MS patients who used other imunomodulatory or immunosuppressant treatment other than GA during the follow-up (e.g., IFN-β, mitoxantrone, cyclophosphamide, cladribine, fludarabine, cyclosporine, total body, azathioprine, methotrexate, IVIG, cellcept, natalizumab, etc.)
MS patients having abnormal kidney function (creatinine clearance <59)

Where it is running

Buffalo Neuroimaging Analysis Center — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.